Swing for the Fences – LDL-C as the Power Hitter
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Safety in oHCM Therapy: How and When to Transition Treatment?
Anjali Owens, MD
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Ahmad Masri, MD, MS
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Michael Nassif, MD, MSc
Cracking the Code of Obstruction: Unmet Needs in oHCM
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Pam R. Taub, MD, FACC, FASPC
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Roxana Mehran, MD, FSCAI
Kappa-Opioid Settings: Real-World Evidence Insights
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Leonie Kraft, MD
CKD-aP Treatment Tool Kit
Quantifying CKD-aP: Tools for Better Care